Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Surefire vs. Endhole for DEB-TACE: Quantifying Hepatic Artery Embolization to Improve Outcomes by Comparing Two Different Catheter Systems for DEB-TACE (QED Study)

NCT02748161 is registered in ClinicalTrials.gov with Surefire Medical, Inc. as lead sponsor.

NCT NCT02748161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02748161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Surefire vs. Endhole for DEB-TACE: Quantifying Hepatic Artery Embolization to Improve Outcomes by Comparing Two Different Catheter Systems for DEB-TACE (QED Study)
Lead sponsor
Surefire Medical, Inc.
Phase
Not applicable
Overall status
Terminated
Start date
August 31, 2015
Completion date
June 15, 2018
Enrollment
170 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma